Canada missed chance to help homegrown vaccines move quickly last spring: developers
OTTAWA — Two vaccine developers in Canada say a lack of federal funding early in the pandemic kept homegrown vaccines from moving as quickly as international versions.
John Lewis, the CEO of Entos Pharmaceuticals in Alberta, says his company is one of six that received about $5 million to move their COVID-19 vaccine along.
But Lewis says other countries invested more than $300 million per company to ensure they had funding to get through the entire vaccine development process.
He says those companies, such as AstraZeneca and Pfizer, now have vaccines approved in dozens of countries.